Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes

Research output: Contribution to journalJournal articleResearchpeer-review

INTRODUCTION: Polycystic ovary syndrome (PCOS) is associated with obesity and insulin resistance. The objective of this cross-sectional study was to investigate the impact of insulin resistance and body mass index (BMI) on inflammatory and hemostatic variables associated with long-term risk of cardiovascular disease in women with PCOS.

MATERIAL AND METHODS: 149 premenopausal women with PCOS were recruited consecutively from April 2010 to February 2012 at three Danish University Hospitals. The study was conducted at the Department of Gynecology and Obstetrics, Herlev University Hospital, Denmark. PCOS was diagnosed in accordance with the Rotterdam criteria and the women were classified into four phenotypes according to BMI and insulin resistance measured by the homeostasis model assessment of insulin resistance index. Body composition was determined by dual-energy X-ray absorptiometry. Main outcome measures were the biomarkers C-reactive protein (CRP), plasminogen activator inhibitor-1 (PAI-1), and von Willebrand factor antigen.

RESULTS: Normal weight insulin-resistant PCOS women were characterized by abdominal obesity and elevated levels of plasma PAI-1. Overweight/obese insulin-resistant PCOS women had increased levels of both PAI-1 and CRP. Of the three Rotterdam criteria, only hyperandrogenemia was significantly associated with the hemostatic risk marker of long-term cardiovascular disease risk.

CONCLUSIONS: Surrogate risk markers for cardiovascular disease are elevated in women with PCOS, especially insulin-resistant and overweight/obese women.

Original languageEnglish
JournalActa Obstetricia et Gynecologica Scandinavica
Volume94
Issue number10
Pages (from-to)1082-9
Number of pages8
ISSN0001-6349
DOIs
Publication statusPublished - Oct 2015

    Research areas

  • Adult, Body Mass Index, C-Reactive Protein, Cardiovascular Diseases, Cross-Sectional Studies, Female, Humans, Insulin Resistance, Phenotype, Plasminogen Activator Inhibitor 1, Polycystic Ovary Syndrome, Prospective Studies, Risk Factors, von Willebrand Factor

ID: 161622743